摘要
原文 | 英語 |
---|---|
頁(從 - 到) | 84-93 |
頁數 | 10 |
期刊 | Annals of Surgical Oncology |
卷 | 14 |
發行號 | 1 |
DOIs | |
出版狀態 | 已發佈 - 2007 |
對外發佈 | 是 |
引用此
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Evaluation of serum amyloid a as a biomarker for gastric cancer. / Chan, De-Chuan; Chen, Cheng-Jueng; Chu, Heng-Cheng 等.
於: Annals of Surgical Oncology, 卷 14, 編號 1, 2007, p. 84-93.研究成果: 雜誌貢獻 › 文章 › 同行評審
}
TY - JOUR
T1 - Evaluation of serum amyloid a as a biomarker for gastric cancer
AU - Chan, De-Chuan
AU - Chen, Cheng-Jueng
AU - Chu, Heng-Cheng
AU - Chang, Wei-Kuo
AU - Yu, Jyh-Cherng
AU - Chen, Yu-Ju
AU - Wen, Li-Li
AU - Huang, Su-Ching
AU - Ku, Chih-Hung
AU - Liu, Yao-Chi
AU - Chen, Jenn-Han
N1 - 被引用次數:54 Export Date: 22 March 2016 CODEN: ASONF 通訊地址: Chan, D.-C.; Division of General Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 電子郵件: chrischan1168@yahoo.com.tw 化學物質/CAS: Serum Amyloid A Protein; Tumor Markers, Biological 參考文獻: Stadtlander, C.T., Waterbor, J.W., Molecular epidemiology, pathogenesis and prevention of gastric cancer (1999) Carcinogenesis, 20, pp. 2195-2208; (1997) Health and Vital Statistics, , Taipei: Department of Health, Executive Yuan, Republic of China; Collard, J.M., Malaise, J., Mabrut, J.Y., Skeletonizing. En-bloc gastrectomy for adenocarcinoma in Caucasian patients (2003) Gastric Cancer, 6, pp. 210-216; Juan, H.F., Chen, J.H., Hsu, W.T., Identification of tumor-associated plasma biomarkers using proteomic techniques: From mouse to human (2004) Proteomics, 4, pp. 2766-2775; Sheu, L.F., Chen, A., Wei, Y.H., Epstein-Barr virus LMP1 modulates the malignant potential of gastric carcinoma cells involving apoptosis (1998) Am J Pathol, 152, pp. 63-74; Yamada, T., Serum amyloid a (SAA): A concise review of biology, assay methods and clinical usefulness (1999) Clin Chem Lab Med, 37, pp. 381-388; Biran, H., Friedman, N., Neumann, P.M., Serum amyloid a (SAA) variations in patients with cancer: Correlation with disease activity, stage, primary site, and prognosis (1986) J Clin Pathol, 39, pp. 794-797; Kimura, M., Tomita, Y., Imai, T., Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma (2001) Cancer, 92 (8), pp. 2072-2075; Glojnaric, I., Casl, M.T., Simic, D., Serum amyloid A protein (SAA) in colorectal carcinoma (2001) Clin Chem Lab Med, 39 (2), pp. 129-133; Kaneti, J., Winikoff, Y., Zimlichman, S., Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer (1984) Urol Res, 12 (5), pp. 239-241; Cho, W.C., Yip, T.T., Yip, C., Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling (2004) Clin Cancer Res, 10 (1 PART 1), pp. 43-52; O'Hanlon, D.M., Lynch, J., Cormican, M., Given, H.F., The acute phase response in breast carcinoma (2002) Anticancer Res, 22, pp. 1289-1293; Rosenthal, C.J., Sullivan, L.M., Serum amyloid A to monitor cancer dissemination (1979) Ann Intern Med, 91, pp. 383-390; (1993) The General Rules for the Gastric Cancer Study. 12th Edn., pp. 30-33. , Japanese Research Society for Gastric Cancer. Tokyo: Kanehara; Sobin, L.H., Wittekind, C.H., (1997) International Union Against Cancer (UICC): TNM Classification of Malignant Tumors, 5th Edn., , New York: John Wiley; Lauren, P., The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma (1965) Acta Pathol Microbiol Scand, 64, pp. 31-49; Juan, H.F., Lin, J.Y., Chang, W.H., Biomic study of human myeloid leukemia cells differentiation to macrophages using DNA array, proteomic, and bioinformatics analytical methods (2002) Electrophoresis, 23, pp. 2490-2504; D'Eril, G.M., Anesi, A., Maggiore, M., Biological variation of serum amyloid A in healthy subjects (2001) Clin Chem, 47, pp. 1498-1499; Shimizu, N., Wakatsuki, T., Murakami, A., Carcinoembryonic antigen in gastric cancer patients (1987) Oncology, 44, pp. 240-244; Nakane, Y., Okamura, S., Akehira, K., Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients (1994) Cancer, 73, pp. 2703-2708; Koga, T., Kano, T., Souda, K., The clinical usefulness of preoperative CEA determination in gastric cancer (1987) Jpn J Surg, 17, pp. 342-347; Sakamoto, K., Haga, Y., Yoshimura, R., Comparative effectiveness of the tumour diagnostics, CA 19-9, CA125 and carcinoembryonic antigen in patients with diseases of the digestive system (1987) Gut, 28, pp. 323-329; Marrelli, D., Roviello, F., De Stefano, A., Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma (1999) Oncology, 57, pp. 55-62; Safi, F., Kuhns, V., Beger, H.G., Comparison of CA72-4, CA19-9 and CEA in the diagnosis and monitoring of gastric cancer (1995) Int J Biol Markers, 10, pp. 100-106; Parsonnet, J., Friedman, G.D., Vandersteen, D.P., Helicobacter pylori infection and the risk of gastric carcinoma (1991) N Engl J Med, 325, pp. 1127-1131; Forman, D., Newell, D.G., Fullerton, F., Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation (1991) BMJ, 302, pp. 1302-1305; Hansen, S., Melby, K.K., Aase, S., Jellium, E., Vollset, S.E., Helicobacter pylori infection and risk of cardia cancer and non-cardia cancer (1999) Scand J Gastroenterol, 4, pp. 353-360; Delanghe, J.R., Langlois, M.R., De Bacquer, D., Mak, R., Capel, P., Van Renterghem, L., De Backer, G., Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease (2002) Atherosclerosis, 160 (2), pp. 471-476; Hagihara, K., Nishikawa, T., Isobe, T., IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system (2004) Biochem Biophys Res Commun, 314 (2), pp. 363-369; Galizia, G., Lieto, E., De Vita, F., Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: Relationship with radicality and outcome (2002) J Interferon Cytokine Res, 22, pp. 473-482; Yamaoka, Y., Kodama, T., Kita, M., Relation between cytokines and Helicobacter pylori in gastric cancer (2001) Helicobacter, 6, pp. 116-124; De Vita, F., Romano, C., Orditura, M., Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator (2001) J Interferon Cytokine Res, 21, pp. 45-52; Wu, C.W., Wang, S.R., Chao, M.F., Serum interleukin-6 levels reflect disease status of gastric cancer (1996) Am J Gastroenterol, 91, pp. 1417-1422; Kabir, S., Daar, G.A., Serum levels of interleukin-1, interleukin-6 and tumor necrosis factor-alpha in patients with gastric cancer (1995) Cancer Lett, 95, pp. 207-212; Tatsuno, I., Nishikawa, T., Sasano, H., Interleukin 6-producing gastric carcinoma with fever, hypergammaglobulinemia, and plasmacytosis in bone marrow (1994) Gastroenterology, 107, pp. 543-547; Lin, M.T., Juan, C.Y., Chang, K.J., IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1 (2001) Carcinogenesis, 22, pp. 1947-1953; Ding, S.Z., Cho, C.H., Lam, S.K., Regulation of IL-6 production in human gastric epithelial cell line MKN-28 (2000) Cytokine, 12, pp. 1129-1135
PY - 2007
Y1 - 2007
N2 - Background: Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans. Methods: Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides. Results: The mean SAA concentration was higher in gastric cancer patients (88.54 ± 50.44 mg/l) than in healthy subjects (3.36 ± 2.29 mg/l) and gastric ulcer patients (10.48 ± 8.97 mg/l) (P <.05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren's histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P <.0001) and lymph node status (P <.05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P <.05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells. Conclusions: These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up. © 2006 Society of Surgical Oncology.
AB - Background: Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans. Methods: Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides. Results: The mean SAA concentration was higher in gastric cancer patients (88.54 ± 50.44 mg/l) than in healthy subjects (3.36 ± 2.29 mg/l) and gastric ulcer patients (10.48 ± 8.97 mg/l) (P <.05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren's histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P <.0001) and lymph node status (P <.05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P <.05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells. Conclusions: These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up. © 2006 Society of Surgical Oncology.
KW - Mass spectrometry (MS)
KW - Serum amyloid A (SAA) protein
KW - Serum marker
KW - Stomach neoplasm
KW - biological marker
KW - serum amyloid A
KW - article
KW - blood vessel
KW - cancer cell
KW - cancer patient
KW - cancer survival
KW - concentration response
KW - controlled study
KW - correlation analysis
KW - disease marker
KW - evaluation
KW - follow up
KW - gastrectomy
KW - human
KW - human tissue
KW - immunohistochemistry
KW - immunoreactivity
KW - lymph node
KW - major clinical study
KW - measurement
KW - mortality
KW - multivariate analysis
KW - protein expression
KW - stomach cancer
KW - stomach ulcer
KW - tissue section
KW - tumor recurrence
KW - Adenocarcinoma
KW - Aged
KW - Female
KW - Gastrectomy
KW - Humans
KW - Immunohistochemistry
KW - Male
KW - Middle Aged
KW - Serum Amyloid A Protein
KW - Stomach Neoplasms
KW - Stomach Ulcer
KW - Survival Analysis
KW - Tumor Markers, Biological
U2 - 10.1245/s10434-006-9091-z
DO - 10.1245/s10434-006-9091-z
M3 - Article
VL - 14
SP - 84
EP - 93
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 1
ER -